Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats
Kayla J. Colvin, Henry S. Killen, Maxwell J. Kanter, et al.
Behavioural Brain Research (2021) Vol. 421, pp. 113726-113726
Closed Access | Times Cited: 14

Showing 14 citing articles:

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
Fatima Quddos, Zachary Hubshman, Allison N. Tegge, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 53
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 994-994
Open Access | Times Cited: 34
Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin
Maximilian Tufvesson‐Alm, Olesya T. Shevchouk, Elisabet Jerlhag
Frontiers in Psychiatry (2023) Vol. 13
Open Access | Times Cited: 20
IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns, Elizabeth H. Tressler, Leandro F. Vendruscolo, et al.
Pharmacological Research (2024) Vol. 207, pp. 107312-107312
Open Access | Times Cited: 6
Metabolic hormone action in the VTA: Reward-directed behavior and mechanistic insights
Caroline E. Geisler, Matthew R. Hayes
Physiology & Behavior (2023) Vol. 268, pp. 114236-114236
Open Access | Times Cited: 15
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access
Animal studies reveal that the ghrelin pathway regulates alcohol-mediated responses
Elisabet Jerlhag
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 9
Is there a risk for Semaglutide Misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset
Stefania Chiappini, Rachel Vickers‐Smith, Duccio Papanti, et al.
(2023)
Open Access | Times Cited: 6
Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention: A Randomized Clinical Trial
Ryan T. Hurt, Ivana T. Croghan, Darrell R. Schroeder, et al.
Mayo Clinic Proceedings Innovations Quality & Outcomes (2022) Vol. 6, Iss. 5, pp. 465-474
Open Access | Times Cited: 4
Mesolimbic exendin-4 attenuates reward salience evoked by neuropeptide Y and ghrelin
Alev M. Brigande, Janet Guss Darwich, Paul J. Currie
Behavioural Brain Research (2022) Vol. 440, pp. 114249-114249
Closed Access | Times Cited: 4
Cannabidiol or ketamine for preventing the impact of adolescent early drug initiation on voluntary ethanol consumption in adulthood
M. Julia García‐Fuster, Carles Colom-Rocha, Cristian Bis‐Humbert
Research Square (Research Square) (2024)
Open Access
Ghrelin system and GLP-1 as potential treatment targets for alcohol use disorder
Elisabet Jerlhag
International review of neurobiology (2024), pp. 401-432
Closed Access
Cannabidiol or ketamine for preventing the impact of adolescent early drug initiation on voluntary ethanol consumption in adulthood
Carles Colom-Rocha, Cristian Bis‐Humbert, M. Julia García‐Fuster
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, et al.
(2023)
Open Access | Times Cited: 1
Page 1

Scroll to top